REM sleep behaviour disorder (RBD), a parasomnia that is characterized by a loss of normal skeletal muscle atonia during REM sleep and elaborate motor activity associated with oneiric content, is one of the most common non-motor symptoms of Parkinson's disease (PD)[@b1][@b2]. Epidemiological investigation demonstrated that RBD, which has a prevalence of \<1% in the general population[@b3][@b4], is a common disorder that occurs in 15--75% of patients with PD, especially males over 50 years of age[@b5][@b6][@b7][@b8]. RBD frequently leads to serious injuries to PD patients, e.g., falling out of bed, and patients can harm their sleeping partner while dreaming[@b1][@b9].

RBD is considered a heralding disorder or early marker of α-synucleinopathies, including dementia with Lewy bodies (DLB), multiple system atrophy (MSA), and Parkinson's disease (PD)[@b10][@b11][@b12]. A longitudinal cohort study revealed that RBD appears several years or even decades before the onset of the motor symptoms of PD[@b13]. Furthermore, 38% of patients developed a parkinsonian syndrome approximately 3.7 years after an initial diagnosis of idiopathic RBD[@b10].

Current research suggests that neuronal degeneration of brainstem nuclei, including the pontine tegmental area and medulla, is the pathophysiological cornerstone of RBD[@b14]. However, there are still a remarkable number of PD patients who do not display RBD symptoms, even with long disease duration. Thus, there are likely additional factors involved in the occurrence of PD-related RBD (PDRBD) other than neuronal degeneration.

Numerous studies are available on the prevalence, clinical characteristics and disease staging of RBD. However, systemic meta-analyses in large samples for comparing the clinical variations between patients with PDRBD and those with PD alone (Non-RBD) are scarce. Therefore, the primary aims of our study were to compare the clinical characteristics of PDRBD and Non-RBD. This study was conducted with data originating from multiple studies with an overall moderate quality.

Methods
=======

Data sources and search strategy
--------------------------------

The study protocol was approved by the Clinical Ethics Committee of The First Affiliated Hospital of Anhui Medical University. In accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement[@b15], we undertook a systematic search of PubMed and Embase databases for studies published between January 2000 and August 2016 with a language limitation of English only. The search terms "rapid eye movement", "rem", "rem sleep behavior disorder", or "rapid eye movement sleep behavior disorder" were combined using the Boolean logical operator AND with studies identified by the terms "parkinson", "parkinson's", "parkinson disease", "parkinson's disease", "parkinsonian", "parkinsonian disease" or "parkinsonian disorders". The references in the primary selected articles, relevant reviews and meta-analyses were also examined to identify additional relevant studies.

Data extraction and quality assessment
--------------------------------------

Prospective or retrospective case-control studies that compared PD patients with and without RBD were eligible for inclusion in our meta-analysis. The papers were initially screened on the basis of their titles and/or abstracts by two reviewers (Ruo-lin Zhu and Cheng-juan Xie). For inclusion in the meta-analysis, a study had to meet the following criteria: (1) the original data were published; (2) the diagnosis of PD was confirmed with the U.K. Parkinson's Disease Society Brain Bank criteria or other criteria; (3) the PD incidence data were classified into groups of PDRBD and Non-RBD. Notably, in this meta-analysis, a definition of Confirmed-RBD was made when RBD patients met the criteria described in the International Classification of Sleep Disorders (ICSD), in which polysomnography (PSG) is mandatory; otherwise, the Probable-RBD was defined in RBD patients who were diagnosed based on interview or questionnaires. (4) the study described the number of participants and PD cases, ratio or number of male/female subjects, age, onset age of PD, disease duration, Hoehn-Yahr staging scale for disease activity, and the Unified Parkinson's Disease Rating Scale part III (UPDRS-III) score for motor symptom severity. Studies with inadequate data on the diagnosis of PD and/or RBD and those focused on pathogenic mechanisms were excluded. Articles that included fewer than 20 patients and studies based on animal research were also excluded.

Bias risk and applicability were critically evaluated based on a quantitative 5-point Jadad scale[@b16]. The Jadad scale focuses on 4 critical items, including randomisation (maximum of 2 points), blinding (maximum of 2 points) and an account of all patients (maximum of 1 point). The Jadad scores were determined by two reviewers (Ruo-lin Zhu and Cheng-juan Xie). Scoring disagreements were determined by an arbitrator (Kai Wang).

Statistical analysis
--------------------

The meta-analysis of dichotomous or continuous variables was conducted using the Mantel-Haenszel method with a fixed- or random-effects model (based on the heterogeneity analysis). Data were combined and expressed as odds ratios (ORs) or standardized mean differences (SMDs) for dichotomous and continuous variables, respectively, with 95% confidence intervals (95% CI).

Forest plots were presented with a measure of inconsistency across the trials (the Cochrane Q statistic was calculated from Chi^2^ and the I^2^ statistic) and a test for overall effects (Z). The statistical heterogeneity between studies was assessed with the Cochran's Q-test and I^2^-values. If the Cochran's Q test had a p value \< 0.05, an I^2^ value over 75% was defined as high inconsistency, an I^2^ above 50% was defined as moderate heterogeneity, and an I^2^ below 25% was defined as low levels of inconsistency amongst the included studies[@b17][@b18][@b19].

Funnel plots were produced to detect potential publication bias. All statistical tests and the construction of forest plots were performed using Stata/SE version 13.1 (StataCorp, College Station, TX, USA). The significance level was set at p \< 0.05.

Results
=======

Study identification and methodological quality
-----------------------------------------------

The initial search strategy yielded 3,341 potentially relevant studies from the PubMed (n = 1,117) and Embase (n = 2,224) databases. After 1,159 duplicates were removed, the titles and/or abstracts of 2,182 citations were reviewed, and 839 studies were excluded. The remaining 1,343 full-text articles were retrieved for further evaluation. Another 1,187 studies were excluded because they were reviews (n = 655), case reports (n = 166), animal studies (n = 306) or editorials (n = 50). Ultimately, 31 articles[@b1][@b2][@b7][@b8][@b20][@b21][@b22][@b23][@b24][@b25][@b26][@b27][@b28][@b29][@b30][@b31][@b32][@b33][@b34][@b35][@b36][@b37][@b38][@b39][@b40][@b41][@b42][@b43][@b44][@b45][@b46] were included in our analysis ([Fig. 1](#f1){ref-type="fig"}). The diagnosis of Confirmed-RBD and Probable-RBD were defined in 19 and 12 studies respectively ([Table 1](#t1){ref-type="table"}). No disagreements on study selection occurred between the reviewers.

The studies used for in our meta-analysis consisted of 7,380 randomised subjects, which ultimately encompassed 5,815 participants (PDRBD, n = 2,319, mean group size = 74.8; and Non-RBD, n = 3,496, mean group size n = 112.8) ([Table 1](#t1){ref-type="table"}). Fourteen studies were performed in Asia, 11 in Europe, 5 in North America, and 1 in Australia. The mean age across all subjects ranged from 54.1 to 76.5 years, and approximately 57.6% of patients were male. The onset age of PD ranged from 51.0 to 65.5 years. The mean disease duration of all participants ranged from 4.3--15.3 years. The mean Hoehn-Yahr scale and UPDRS-III score ranged from 0.9 to 3.2 and 0.23 to 190.97, respectively.

PDRBD patients were further classified into subgroups for two studies: clinical or subclinical RBD in the study conducted by Nomura *et al*.[@b36] and PD-RBD with and without hallucinations in the study conducted by Sinforiani *et al*.[@b40]. The subgroup data were included independently in the meta-analysis for the variables of sex, age, disease duration, Hoehn-Yahr scale, and UPDRS-III score. The methodological quality was appraised for all studies included in the meta-analysis. Overall, the included studies were of moderate methodological quality according to the Jadad scale ([Table 1](#t1){ref-type="table"}).

Summary of effects
------------------

With regard to sex, a total of 5,685 PD patients, including 2,252 PDRBD patients and 3,433 Non-RBD patients, from 30 studies were analysed. The study by Vendette *et al*.[@b43] was not included because the gender ratio or number was not reported. The proportion of male patients was 57.8% (males in PDRBD, n = 1,298 and males in Non-RBD, n = 1,988). High-quality evidence that showed male patients had an increased risk of RBD. Overall, male patients with PD were more likely to develop Confirmed-RBD than female patients (OR = 1.25; 95% CI 1.01--1.55; p = 0.038); on the other hand, our meta-analysis showed no significant impact of gender on the occurrence of Probable-RBD in PD patients (OR = 1.08; 95% CI 0.86--1.34; p = 0.516). There was moderate heterogeneity across studies for analysis of Confirmed-RBD (I^2^ = 27.1%; p = 0.139) and no heterogeneity for Probable-RBD (I^2^ = 14.7%; p = 0.300) ([Fig. 2A](#f2){ref-type="fig"}). The funnel plot did not suggest substantial asymmetry ([Fig. 3A](#f3){ref-type="fig"}).

With regard to age, a total of 5,134 PD patients, including 2,292 PDRBD patients and 2,842 Non-RBD patients, from 30 studies were analysed. The study by Boot *et al*.[@b22] was not included because the age of patients was demonstrated as a median (25^th^ percentile, 75^th^ percentile). Overall, elderly patients with PD were more likely to develop Confirmed-RBD than younger PD patients (SMD = 0.25; 95% CI 0.14--0.36; p = 0.000); and no significant effect of age on the occurrence of Probable-RBD (SMD = 0.09; 95% CI −0.02--0.24; p = 0.129). There was low heterogeneity across studies for analysis of Confirmed-RBD (I^2^ = 38.9%; p = 0.036) and no heterogeneity for Probable-RBD (I^2^ = 21.2%; p = 0.242) ([Fig. 2B](#f2){ref-type="fig"}). The funnel plot did not show evidence of asymmetry ([Fig. 3B](#f3){ref-type="fig"}).

The onset age of PD was reported in 12 studies, which included a total of 3,143 patients (1,448 PDRBD and 1,695 Non-RBD). The onset age of PD was 51.0 to 63.6 years for PDRBD patients and 48.6 to 65.5 years for Non-RBD patients. The meta-analysis showed no significant effect of onset age on the occurrence of Confirmed-RBD in PD patients (SMD = 0.08; 95% CI −0.03--0.18; p = 0.154); similarly, no significant effect of onset age on the occurrence of Probable-RBD (SMD = −0.05; 95% CI −0.23--0.14; p = 0.628). The inconsistency amongst the included studies was low (I^2^ = 5.3%; p = 0.386) and moderate (I^2^ = 54.7%; p = 0.050) respectively ([Fig. 2C](#f2){ref-type="fig"}). No clear evidence of asymmetry was demonstrated in the funnel plot ([Fig. 3C](#f3){ref-type="fig"}).

Twenty-eight studies reported a difference in disease duration between PDRBD and Non-RBD patients. A total of 2,623 PDRBD patients (mean disease duration from 4.8 to 15.3 years) and 2,111 Non-RBD patients (mean disease duration from 4.3 to 13.9 years) were included in the meta-analysis. A longer disease duration increased the risk of both of Confirmed-RBD and Probable-RBD in PD patients (SMD = 0.30; 95% CI 0.22--0.37; p = 0.000 and SMD = 0.29; 95% CI 0.19--0.39; p = 0.000). There was no significant inconsistency across the studies (I^2^ = 0.0%; p = 0.757 and 0.0%; p = 0.948 respectively) ([Fig. 2D](#f2){ref-type="fig"}). The funnel plot did not suggest asymmetry ([Fig. 3D](#f3){ref-type="fig"}).

Sixteen studies reported a difference in the Hoehn-Yahr score between PDRBD (n = 986) and Non-RBD patients (n = 1,496). The combined effect size was low but statistically significant for both of Confirmed-RBD and Probable-RBD (SMD = 0.30; 95% CI 0.19--0.40; p = 0.000 and SMD = 0.30; 95% CI 0.19--0.44; p = 0.000). There was no inconsistency across the studies (I^2^ = 0.0%; p = 0.642 and I^2^ = 0.0%; p = 0.564 respectively) ([Fig. 2E](#f2){ref-type="fig"}), and the funnel plot did not suggest asymmetry ([Fig. 3E](#f3){ref-type="fig"}).

Twenty-two studies described the UPDRS-III score for PDRBD patients (n = 1,162; mean score 1.19--38.7) and Non-RBD patients (n = 1,836; mean score 1.1--30.7). The UPDRS-III score was higher in Confirmed-RBD and Probable-RBD patients compared with Non-RBD patients (SMD = 0.38; 95% CI 0.14--0.61; p = 0.002 and SMD = 0.26; 95% CI 0.11--0.41; p = 0.001). True heterogeneity across studies was high for Confirmed-RBD (I^2^ = 78.9%; p = 0.0) and none for Probable-RBD (I^2^ = 15.0%; p = 0.315) ([Fig. 2F](#f2){ref-type="fig"}). Two conspicuous studies[@b8][@b32] that were out of range were revealed in the funnel plot ([Fig. 2F](#f2){ref-type="fig"}). Removing these studies yielded a significant effect of the UPDRS-III score on the occurrence of RBD (SMD = 0.29; 95% CI 0.20--0.38; p = 0.000); however, heterogeneity was not observed across the studies (I^2^ = 17.7%; p = 0.221). Notably, UPDRS-III test performed on the state of "on", "off" and unknown was reported in 3[@b8][@b40][@b43], 4[@b8][@b30][@b40][@b44] and 17[@b1][@b7][@b20][@b23][@b24][@b25][@b26][@b27][@b28][@b31][@b32][@b34][@b35][@b39][@b41][@b42][@b46] of the original studies respectively, which is inappropriate for the further sub-group analysis in this meta-analysis. Therefore, the findings concerning the connection between UPDRS-III score and the occurrence of RBD should be interpreted more cautiously.

Discussion
==========

In the last decade, numerous studies evaluated the clinical factors associated with the occurrence of RBD in PD patients. However, the results are varied due to the diverse criteria for a diagnosis of RBD, different data sources and insufficient sample sizes in most studies. Thus, the relationship between RBD and PD remains unclear.

To summarize these previous studies and obtain a more comprehensive conclusion, we performed a meta-analysis of 33 studies with a total of 5,919 subjects who were diagnosed with PD, including 2,411 PDRBD patients. To our knowledge, this is the first meta-analysis that systematically estimated the clinical factors related to RBD in PD patients. Our findings demonstrated that Confirmed-RBD patients showed the following characteristics compared to PD patients with normal REM sleep behaviour: male, older, longer disease duration, higher disease activity (Hoehn-Yahr scale) and higher motor examination (UPDRS-III) score; while the Probable-RBD patients demonstrated the different clinical features compared to RBD patients in disease duration, disease activity and motor examination.

Previous studies suggested that the incidence of PD is greater in men than women due to the neuroprotective effects of oestrogen via stimulation of dopamine neurotransmission and greater levodopa bioavailability[@b47][@b48] and/or the variant gene expression patterns in dopamine (DA) neurons in the substantia nigra pars compacta (SNc) between males and females[@b49]. Similar to previous reports, our meta-analysis demonstrated that male PD patients had a higher risk for RBD.

Evidence suggests that the pathophysiology of sleep disturbances in PD includes degenerative changes and structural lesions in brainstem areas, particularly the dorsal midbrain and pons, that are related to sleep-wake activity and sleep regulation[@b14]. With regards to clinical features, RBD was reported to be associated with older age, longer PD duration, higher disease severity expressed by Hoehn-Yahr scale, higher UPDRS motor and non-motor symptom scores, more severe motor fluctuation, and higher levodopa dosage for antiparkinsonian treatment, but there was no difference in onset age in PD patients when compared with Non-RBD patients[@b8][@b41][@b50][@b51]. These findings suggest that RBD in PD represents a more severe neurodegenerative process when compared with non-RBD.

At the time, our meta-analysis was conducted using all of the available literature sources that compared the clinical profiles of PD patients with and without RBD. Therefore, we consider these results to be comprehensive and valid. However, some limitations in our analysis and in the individual studies should be considered when interpreting our findings.

Previous studies revealed that antidepressants can produce dream-enactment behavior, reduce REM sleep atonia, and finally precipitate or aggravate RBD[@b22][@b52][@b53]. Even though the details for the mechanisms are unclear, the treatment of antidepressants especially selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors have been implicated in the occurrence of RBD in patients with PD[@b22]. However, in this meta-analysis, we cannot distinguish primary RBD from RBD linked to antidepressants since the data were insufficient in the original articles. Besides, in several of the included studies[@b1][@b2][@b20][@b22][@b24][@b25][@b28][@b29][@b30][@b31][@b33][@b36][@b37][@b38][@b40][@b44][@b45], RBD was diagnosed based on a questionnaire or clinical manifestations but not confirmed with PSG. PSG can detect muscle activation patterns during REM sleep, including aberrant chin muscle tone, limb jerking, and hyperkinetic or violent behaviour; however, this technique is not part of the mandatory criteria for a clinical diagnosis[@b2][@b54]. Regardless, PSG is considered the "gold standard" because it provides objective parameters of primary sleep behaviour in PD patients[@b55]. Thus, a lack of PSG confirmation for an RBD diagnosis might have led to a biased prevalence of RBD in PD patients in our meta-analysis.

Heterogeneity amongst the individual studies is inevitable in meta-analyses because of variability in design characteristics and the relatively poor quality of reporting in primary studies. In this study, several high-quality studies were removed due to data that were deemed inappropriate for our meta-analysis, i.e., data that would increase the heterogeneity and weaken the stringency of the meta-analysis. The deficiencies in the data prevented the inclusion of clinical symptoms (wearing-off/fluctuations, dyskinesia, hallucinations, restless legs syndrome, hypertension, or constipation), psychological assessment parameters (Beck Depression Inventory, BDI and Mini Mental State Examination, MMSE), and treatment (e.g., Levodopa dosage and course duration) in the meta-analysis.

In summary, our data suggest that the clinical characteristics between PD patients with and without RBD are distinct, indicating that PDRBD might represent a variant pattern of neurodegeneration in PD patients. However, the limitations of our study require a cautious interpretation of the identified risk factors for RBD in PD patients. Additional investigations with a more comprehensive design are needed to determine the distinct features of PDRBD patients.
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###### Demographic and clinical characteristics of patients with Parkinson's disease in the included studies.

  Year                                                      Author             Source          Diagnostic criteria for PD; Disease Characteristics           Diagnosis tool for RBD      Participants (n)    Age (mean ± SD, year)              Gender (M/F)              Jadad score
  ------------------------------------------------- ----------------------- ------------- -------------------------------------------------------------- ------------------------------ ------------------ ------------------------- ----------------------------------- -------------
  **Confirmed RBD**                                                                                                                                                                                                                                                      
  2015                                                  Arnulf *et al*.        France                                 PDSBB                                           ICSD                     114              RBD: 62.8 ± 6.8                     80/34                      4
  NRBD: 56.8 ± 10.5                                                                                                                                                                                                                                                      
  2013                                                  Fabio *et al*.       Switzerland                                NR                                      PSG + RBDSQ (≥6)                20              RBD: 65.5 ± 7.3                     13/7                       4
  NRBD: 65.8 ± 9.7                                                                                                                                                                                                                                                       
  2008                                                 Gjerstad *et al*.       Norway             Clinical criteria (Larsen 1994); probable RBD                       ICSD                     245              RBD: 71.6 ± 7.9                    114/117                     3
  NRBD: 73.7 ± 8.5                                                                                                                                                                                                                                                       
  2014                                                   Gong *et al*.          China                                 PDSBB                                          ICSD-2                    120           66.16 ± 9.33 (44--83)                  70/42                      4
  2015                                                 Jankovic *et al*.       Serbia                                 PDSBB                                     ICSD-2 + RBDQ-HK                97                62.1 ± 8.8                        56/41                      2
  2014                                                   Kim *et al*.           Korea                                 PDSBB                                          ICSD-R                    944               63.67 ± 9.33                      448/496                     2
  2015                                                   Kim *et al*.           Korea                                   NR                                           ICSD-R                    124           62.98 ± 7.87 (34--78)                  40/50                      2
  2009                                                   Lee *et al*.           Korea                                 PDSBB                                          ICSD-R                    447                63.8 ± 9.2                       207/240                     2
  2016                                                   Lim *et al*.           Korea                                 PDSBB                                   PSG + RBDSQ-K (\>5)               38              RBD: 69.8 ± 6.4                     20/18                      2
  NRBD: 69.7 ± 7.2                                                                                                                                                                                                                                                       
  2014                                                 Neikrug *et al*.          USA                                    NR                                    ICSD-2 + RBDSQ (≥5)              183            67.2 ± 9.4 (47--89)                   43/19                      4
  2013                                                  Nomura *et al*.         Japan                  PDSBB; Clinical and subclinical RBD                           ICSD-2                     82                74.3 ± 7.2          28/31[†](#t1-fn3){ref-type="fn"};        4
  22/33[\#](#t1-fn4){ref-type="fn"}                                                                                                                                                                                                                                      
  2012                                                 Postuma *et al*.        Canada                                 PDSBB                                          ICSD-2                     42              RBD: 70.5 ± 7.4                     34/8                       4
  NRBD: 67.5 ± 10.6                                                                                                                                                                                                                                                      
  2006                                                Sinforiani *et al*.       Italy                       PDSBB; PD at least 5 years                                ICSD                     110            NRBD: 63.03 ± 8.17;               RBD-1: 42/24                   3
  RBD-1[§](#t1-fn1){ref-type="fn"}: 66.03 ± 9.19;        RBD-2: 42/33                                                                                                                                                                                                    
  RBD-2[‡](#t1-fn2){ref-type="fn"}: 69.58 ± 7.42                                                                                                                                                                                                                         
  2011                                               Sixel-Doring *et al*.     Germany                                PDSBB                                          ICSD-2                    463                RBD: 69 ± 8                      288/169                     4
  NRBD: 66 ± 11                                                                                                                                                                                                                                                          
  2013                                                 Sorensen *et al*.       Denmark                                  NR                                            ICSD                      23              RBD: 62.5 ± 6.9                     14/9                       3
  NRBD: 60.8 ± 6.7                                                                                                                                                                                                                                                       
  2007                                                 Vendette *et al*.       Canada                         PDSBB; H-Y stage I-III                                 ICSD-2                     34             RBD: 65.61 ± 7.73                     NR                        4
  NRBD: 65.13 ± 7.69                                                                                                                                                                                                                                                     
  2011                                                  Vibha *et al*.          India                                 PDSBB                                          ICSD-R                    134             RBD: 61.27 ± 8.56                    90/44                      2
  NRBD: 57.57 ± 11.85                                                                                                                                                                                                                                                    
  2009                                                 Yoritaka *et al*.        Japan            Clinical criteria (Calne, 1992); H-Y stage I--IV                    ICSD-R                    150                68.5 ± 9.8                        70/80                      3
  2016                                                  Zhang *et al*.          China                            PDSBB; MMSE \>21                                    ICSD-2                     46             RBD: 66.71 ± 7.21                    36/10                      4
  NRBD: 62.46 ± 4.8                                                                                                                                                                                                                                                      
  **Probable RBD**                                                                                                                                                                                                                                                       
  2016                                                 Arnaldi *et al*.         Italy         Clinical criteria (Gelb 1999); de novo, drug-naïve PD                   MSQ                       38              RBD: 72.8 ± 6.2                     24/14                      3
  NRBD: 70.6 ± 7.1                                                                                                                                                                                                                                                       
  2012                                                   Boot *et al*.           USA                   Mayo Clinic Study of Aging; UPDRS ≥4                           MSQ                      2050            RBD: 78 (75, 82)                    455/196                     2
  NRBD: 77 (74, 82)                                                                                                                                                                                                                                                      
  2015                                                 Fantini *et al*.        France                                 PDSBB                                    RBD1Q + RBDSQ (≥6)              216              RBD: 67.3 ± 9.9                    130/86                      3
  NRBD: 66.4 ± 11.6                                                                                                                                                                                                                                                      
  2013                                                   Ford *et al*.        Australia                               PDSBB                                           MSQ                      124              RBD: 66.4 ± 9.9                     84/40                      4
  NRBD: 65.8 ± 10.9                                                                                                                                                                                                                                                      
  2015                                                    Hu *et al*.           China                          PDSBB; Probable RBD                                 RBDSQ (≥6)                  225            RBD: 61.19 ± 11.76                   117/108                     3
  NRBD: 59.79 ± 10.37                                                                                                                                                                                                                                                    
  2016                                                   Kim *et al*.           Korea                                   NR                                        RBDSQ-K (≥5)                  42                62.1 ± 8.8                        18/24                      2
  2012                                                 Kotagal *et al*.          USA                                  PDSBB                                MSQ (not confirmed by PSG)           80              RBD: 63.4 ± 6.7                     60/20                      3
  NRBD: 65.3 ± 7.1                                                                                                                                                                                                                                                       
  2014                                                  Mahale *et al*.         India                                 PDSBB                                          RBDSQ                     156                55.4 ± 11.2                      119/38                      2
  2012                                                  Nihei *et al*.          Japan                                 PDSBB                                         RBDSQ-J                    469          71.0 ± 8.3 (44.4--91.8)                219/250                     3
  2005                                                Ozekmekci *et al*.       Turkey       NR; Movement disorders and injurious behavior during sleep    Clinical diagnostic criteria          70              RBD: 67.2 ± 8.6                     54/16                      2
  NRBD: 67.6 ± 9.19                                                                                                                                                                                                                                                      
  2013                                                Poryazova *et al*.     Switzerland   Questionnaire on sleep-wake disorders and PD characteristics            RBDSQ (≥6)                  417                  69 ± 9                         273/131                     3
  2013                                                  Suzuki *et al*.         Japan                          PDSBB; Probable RBD                                RBDSQ-J (≥5)                  77                69.7 ± 8.9                        40/37                      4

**RBD**: rapid eye movement sleep behavior disorder; **NRBD**: Non-RBD; **Confirmed-RBD**: patients diagnosed according to the ICSD-2 criteria, with PSG confirmation; **Probable-RBD**: diagnosis based on interview/questionnaires, w/o PSG reconfirmation; **PDSBB**: U.K. Parkinson's Disease Society Brain Bank criteria; **MSQ**: Mayo Sleep Questionnaire; **H-Y:** Hoehn-Yahr staging scale; **ICSD**: the International Classification of Sleep Disorders criteria for RBD; **MMSE**: Mini Mental State Examination; **RBDSQ**: the RBD screening questionnaire; **PSG**: Polysomnography.

^§^**RBD-1:** PD-RBD w/o hallucinations.

^‡^**RBD-2:** PD-RBD with hallucinations; **NR**: Not reported.

^†^Clinical RBD.

^\#^Subclinical RBD.

[^1]: These authors contributed equally to this work.
